Oct 10, 2024
Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE(TM) DS Delivery System in U.S. Hospitals
Sep 17, 2024
Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect(TM) Injector
Aug 06, 2024
Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect(TM) Injector in the U.S.
Aug 06, 2024
Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance
Aug 05, 2024
Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million
Jun 05, 2024
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress
Mar 11, 2024
Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients
Mar 04, 2024
Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands
Mar 01, 2024
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect(TM) Injector
Jan 22, 2024
Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress
Feb 12, 2021
Mallinckrodt Provides Regulatory Update on StrataGraft®
Jan 29, 2021
Mallinckrodt Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index
Nov 16, 2020
Mallinckrodt Announces Real World Data on Hepatorenal Syndrome (HRS) and Acute Kidney Injury (AKI) in Patients with Liver Disease at The Liver Meeting Digital Experience
Nov 16, 2020
Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience
Oct 14, 2020
Mallinckrodt Receives Court Approval of "First Day" Motions to Support Business Operations
Oct 12, 2020
Mallinckrodt Secures Broad Consensus with Key Stakeholders on Comprehensive Chapter 11 Restructuring
Aug 10, 2020
Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft® Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns
Aug 04, 2020
Mallinckrodt plc Reports Earnings for the Second Quarter 2020 and Highlights Pipeline Advancements
Jul 15, 2020
Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Advisory Committee Voted to Recommend Terlipressin for Approval to Treat Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Jun 17, 2020
Mallinckrodt to Present at the BMO Prescriptions for Success Healthcare Conference